Remogliflozin A (Synonyms: GSK189074) |
| Catalog No.GC18762 |
La remogliflozina A es un inhibidor potente y selectivo de SGLT2 (cotransportador de sodio-glucosa 2) con Kis de 12,4 y 26 nM para SGLT2 humano y de rata, respectivamente.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 329045-45-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Remogliflozin A is a potent inhibitor of sodium-glucose transporter 2 (SGLT2; Kis = 12.4 and 26 nM for human and rat SGLT2, respectively). It is selective for SGLT2 over SGLT1 (Kis = 4,520 and 997 nM for human and rat SGLT1, respectively). Following administration of a prodrug, remogliflozin etabonate, that is rapidly converted to remogliflozin A in vivo, rat urinary glucose excretion increases and plasma glucose and insulin concentrations decrease. Similar effects are observed following oral administration of remogliflozin etabonate to rats with diabetes induced by streptozotocin and db/db mice with hyperinsulinemia and obesity.
Review for Remogliflozin A
Average Rating: 5 (Based on Reviews and 38 reference(s) in Google Scholar.)
Review for Remogliflozin A
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *